SGMT Stock Forecast: Sagimet Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$9.08
−5.61% on the day

The 12 Wall Street analysts covering Sagimet Biosciences, Inc. hold a median 12-month price target of $27 — +197.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 35 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$692.0M
Ticker Nerd rank
35/ 100
Median analyst target
$27
Analysts covering
12
Revenue$0.0
Operating income−$15.8M
Net income−$14.0M
Free cash flow−$11.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.2%
1M
−6.8%
YTD
+53.4%
1Y
+24.9%
From 52W high
−20.4%
From 52W low
+99.6%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Sagimet Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
35/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
79
Growth
69
Value
65
Quality
50
Revisions
28
Accruals
23
Volatility
21
Issuance
18

Momentum (79): The shares have been drifting up relative to others.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SGMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26SGMTHigh $50Median $27Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11
Buy
0
Hold
1
Sell
$7
Low
$27
Median
$50
High

The green dot is the last close — the median target sits +197.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Nov 2026Canaccord GenuityMaintainsBuy$56 → $50
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$29
2 Oct 2026GuggenheimMaintainsBuy$25 → $26
1 Oct 2026CitizensMaintainsMarket Outperform$29 → $27
1 Oct 2026OppenheimerMaintainsOutperform$33 → $38
24 Sept 2026Goldman SachsReinstatesSell$7.00
9 Sept 2026BarclaysUpgradeOverweight$8.00 → $18
9 Sept 2026Cantor FitzgeraldInitiatesOverweight$11
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$29
14 Aug 2026CitizensMaintainsMarket Outperform$12 → $29
12 Aug 2026Canaccord GenuityMaintainsBuy$49 → $56
19 May 2026CitizensMaintainsMarket Outperform$35 → $12
4 May 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026GuggenheimMaintainsBuy—
11 Mar 2026HC Wainwright & Co.ReiteratesBuy—
3 Feb 2026GuggenheimInitiatesBuy—
3 Feb 2026HC Wainwright & Co.ReiteratesBuy—
28 Jan 2026BarclaysInitiatesEqual-Weight—
14 Nov 2025CitizensMaintainsMarket Outperform—
22 Oct 2025Clear StreetInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SGMT.

Market Radar

This page is one stock. Monday covers all of them.

SGMT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SGMT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Sagimet Biosciences, Inc. returned +24.9% against +6.9% for the S&P 500, dividends included.

SGMT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26SGMTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.3×

Cheaper than 38% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−29.5%

Higher than 28% of US stocks

Return on assets
−18.2%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sagimet Biosciences, Inc. has a market value of $692.0M and an enterprise value of $452.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$47.1M.

  • Diluted earnings per share, trailing twelve months: −$1.28.

  • Free cash flow in the twelve months to 30 June 2026: −$41.7M.

  • Shares outstanding: 61.8M.

  • Sagimet Biosciences, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

SGMT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SGMTSagimet Biosciences, Inc.$692.0M35
PRMEPrime Medicine, Inc.$643.9M63
IAMIambic Therapeutics, Inc.$621.4M1
ABUSArbutus Biopharma Corp.$616.2M82
KURAKura Oncology, Inc.$613.4M53
OLMAOlema Oncology, Inc.$611.8M25
NVCTNuvectis Pharma, Inc.$666.8M50

Take a look at SGMT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Sagimet Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SGMT

What is the SGMT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Sagimet Biosciences, Inc. have a median 12-month price target of $27, with estimates ranging from $7 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGMT stock a buy right now?

Of the 12 analysts covering Sagimet Biosciences, Inc., 11 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sagimet Biosciences, Inc. 35 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGMT?

As at 21 Nov 2026, Sagimet Biosciences, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).

Will SGMT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +197.4% from the last close, and Ticker Nerd's factor model ranks Sagimet Biosciences, Inc. 35 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGMT stock forecast for 2030?

No analyst covering Sagimet Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $50 over the next 12 months.

How has SGMT stock performed over the past year?

Sagimet Biosciences, Inc. returned +24.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sagimet Biosciences, Inc. do?

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis.

Company

About Sagimet Biosciences, Inc.

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis. Its lead assets include oral therapies under development for conditions such as metabolic dysfunction-associated steatohepatitis and related disorders, along with additional research programs in dermatology and oncology. Sagimet operates as a single business segment devoted to drug discovery, clinical development, and eventual commercialization of targeted therapies. The stock is used by investors to gain exposure to a specialty biotechnology company centered on in-house discovered, mechanism-based treatments for diseases with limited therapeutic options.

CEO Mr. David A. Happel · 16 employees · United States · https://www.sagimet.com